Online ISSN: 2515-8260

Author : Basalingappa, Kanthesh M


Biogenic Nanoparticles From Allium Sativum And Its Bioactives Applications

Shwetha Subbanna; Gopenath TS; Kanthesh M Basalingappa

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 212-232

Recent development in the synthesis of nanoparticles relies on the use of green chemistry with safe, biocompatible materials to manufacture composites, structures, and formulations based on nano for specific applications. The basic goal of green nanoparticle synthesis is to make use of the element's specific physicochemical and biological properties by linking bioactive from prokaryotes and eukaryotes for applications in various basic and applied science fields. Biogenic methods have the potential to provide advanced strategies for surface/material modification in the increasing carbonaceous materials market.
Garlic is an extensively studied herb known for possessing a wide variety of bioactive. The major proportion of garlic bioactive is organosulfur or thiol based organic compounds that have numerous biological and therapeutic activities and thus target biogenic nanocomponents and formulations for synthesis. There is, however, very scant literature on its use in the agriculture sector. The present review focuses on the synthesis of garlic related nanoparticles and their applications across various scientific fields, and their potential environmental implications when used in agriculture.

Fragile X Syndrome: Epigenetics marks in the Therapy

Shreya shreshtha; Raghu N; Gopenath TS; Parthiban R; Prathibha Rajashekara S; Kanthesh M Basalingappa

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 7048-7055

Fragile X syndrome (FXS) occurs due to the absence of expression of the fragile X intellectual retardation protein and it is an inherited syndrome. FXS is the monogenic form which involves a single gene, or we can say that one of the intellectual disabilities and generally called the most important reason for autism. The main cause of FXS is the deficiency of an RNA-binding protein known as Fragile X Mental Retardation Protein (FMRP). This RNA-binding protein is encrypted by the gene called Fragile X Mental Retardation Gene 1 (FMR1) gene. Multiple roles have been assigned to this protein including shipping of the RNA to translational management of mRNAs. FMRP is the protein that helps the dispatch and translation of lots of mind mRNAs by modulating an activity-based etiquette. Due to the lack of this RNA-binding protein, highbrow disability occurs which is a result of disorganization of a couple of neuronal pathways. In the present scenario, FXS efficient treatment is not available. Here in this paper, we are discussing the FMR1 gene recovery as a probable advance toward the diagnosis of FXS and pressurize on the small molecules which suppresses essential pathways for silencing of a gene which leads to the success in treating FMR1 gene allied disabilities. In conclusion, the therapeutic techniques which have visible foremost success in FXS using genetic and epigenetic manner. There is first-rate progress in basic, preclinical, and translational clinical studies that has explained a lot of molecular, cellular, and system-degree defects in FRAXA which has led to the discovery of some encouraging therapeutic techniques and analysis of this syndrome.